22nd Jan 2025 Plain language summary of the DESTINY-Breast04 study: Trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer
25th Nov 2022 Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study